Use of an ang-(1-7) receptor agonist in acute lung injury

Abstract

The present invention refers to a peptidic or non-peptidic angiotensin-(1-7) (Ang-(1-7)) receptor agonist, preferably a Mas receptor agonist, for the prevention and/or treatment of acute lung injury, preferably acute respiratory distress syndrome.

1 . An Ang-(1-7) receptor agonist for use in the prevention and/or treatment of an acute lung injury in a subject. 
     
     
         2 . The receptor agonist according to  claim 1 , wherein the receptor agonist is a Mas receptor agonist. 
     
     
         3 . The receptor agonist according to  claim 1 , wherein the receptor agonist is a peptidic or non-peptidic agonist. 
     
     
         4 . The receptor agonist according to  claim 3 , wherein the peptidic agonist is an exogenous or endogenous Ang-(1-7) peptide comprising an amino acid sequence according to SEQ ID NO: 1 or is a derivative or analogue thereof. 
     
     
         5 . The receptor agonist according to  claim 3 , wherein the peptidic agonist is a peptide comprising an amino acid sequence according to SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4. 
     
     
         6 . The receptor agonist according to  claim 3 , wherein the peptidic agonist is an exogenous or endogenous NorAng-(1-7) peptide comprising an amino acid sequence according to SEQ ID NO: 5 or is a derivative or analogue thereof. 
     
     
         7 . The receptor agonist according to  claim 3 , wherein the peptidic agonist is an exogenous or endogenous Ang IV peptide comprising an amino acid sequence according to SEQ ID NO: 6 or is a derivative or analogue thereof. 
     
     
         8 . The receptor agonist according to  claim 3 , wherein the peptidic agonist is an exogenous or endogenous Ang III peptide comprising an amino acid sequence according to SEQ ID NO: 7 or is a derivative or analogue thereof. 
     
     
         9 . The receptor agonist according to  claim 3 , wherein the non-peptidic agonist is selected from the group of 1-(p-thienylbenzyl)imidazole compounds, preferably is Ave 0991. 
     
     
         10 . The receptor agonist according to  claim 1 , wherein the acute lung injury is an acute respiratory distress syndrome. 
     
     
         11 . The receptor agonist according to  claim 1 , wherein the acute lung injury is related to a pulmonary or an extrapulmonary lung injury. 
     
     
         12 . The receptor agonist according to  claim 11 , wherein the pulmonary lung injury is selected from the group consisting of inhalation trauma, aspiration trauma, toxic lung oedema, lung infection, preferably pneumonia, lung contusion, and embolism. 
     
     
         13 . The receptor agonist according to  claim 11 , wherein the extrapulmonary lung damage is associated with a disorder selected from the group consisting of sepsis, polytrauma, shock, burn, acute pancreatitis, drug intoxication, alcohol abuse, chronic lung disease, mass transfusion, disseminated intravascular coagulation, erythema, and autoimmune lung disease. 
     
     
         14 . The receptor agonist according to  claim 1 , wherein the subject is a mammal, preferably a human, most preferably an adult human. 
     
     
         15 . A pharmaceutical composition comprising an Ang-(1-7) receptor agonist according to  claim 1  for use in the prevention and/or treatment of an acute lung injury in a subject.